



November 27, 2019

The Manger - Listing **BSE** Limited Corporate Relationship Dept., 1st Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai 400001

National Stock Exchange of India Ltd. Exchange plaza, 5th Floor, Plot No.C/1, G Block

Bandra-Kurla Complex, Bandra (E),

Mumbai 400051

Dear Sir(s),

Sub: Disclosure of Related Party Transactions

Ref: Scrip Code – BSE: 506820, NSE: ASTRAZEN

Pursuant to the provisions of Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we enclose herewith the disclosure of Related Party Transactions for half year ended September 30, 2019 for your information and records.

For AstraZeneca Pharma India limited

Company Secretary & Legal Counsel

AstraZeneca Pharma India Limited

Disclosure of related party transactions for the half year ended 30 September, 2019

In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018 (All amounts in Rs.million, except per share and share data)

(i) Names of related parties and related party relationship

(a) Related parties where control exists and/or where transactions have occurred:

Name of the entity	Name of relationship
Holding Company	AstraZeneca Pharmaccuticals AB, Sweden
Holding Company of AstraZeneca	
Pharmaceuticals AB, Sweden	AstraZeneca AB, Sweden
Holding Company of AstraZeneca AB, Sweden	AstraZeneca Treasury Limited, United Kingdom
Ultimate Holding Company	AstraZencea Ple, United Kingdom
Fellow subsidiaries with whom the company had	AstraZeneca Singapore Pte Ltd, Singapore
transactions during the year	AstraZeneca India Private Limited, India
	AstraZeneca Pharmaceuticals LP, USA
	AstraZeneca UK Limited, United Kingdom
	P.T. AstraZeneca Indonesia
	AstraZeneca Pty Ltd, Australia
Employees' Benefit Plans	AstraZeneca Pharma India Limited Employees Gratuity Fund Trust
	AstraZeneca Pharma India Limited Management Staff Provident Fund Trust
	AstraZeneca Pharma India Limited Management Staff Superannuation Fund Trust
b) Key Management Personnel	
- Managing Director	Mr. Gagandeep Singh Bedi
- Director and Chief Financial Officer	Mr. Rajesh Marwaha
- Non-Executive Directors	Mr. Ian John Parish
	Ms. Weiying Sarah Wang
c) Independent Directors	Mr. Narayan K Seshadri
	Ms. Revathy Ashok
	Ms. Kimsuka Narasimhan



AstraZeneca Pharma India Limited

Trade payables

AstraZeneca AB, Sweden

AstraZeneca Pty Ltd, Australia

AstraZeneca UK Limited, United Kingdom

Disclosure of related party transactions for the half year ended 30 September, 2019

In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulatious, 2018

(All amounts in Rs.million, except per share and share data)

(ii)	Details of the transactions with the related	parties during the period 01 April 2019 to 30 September 2019 :	
(11)	Details of the transactions with the related	parties during the period of April 2017 to 50 September 2017,	

(11)	Details of the transactions with the related parties	s during the period of April 2019 to 50 September 2019;	
	Purchase of materials and traded goods		
	AstraZeneca UK Limited, United Kingdom		1,220.1
	AstraZeneca AB, Sweden		103.2
	Payment towards reimbursement of expenses		
	AstraZeneca UK Limited, United Kingdom		8.2
	AstraZeneca Pty Ltd, Australia		2.0
	Sale of services		
	AstraZeneca AB, Sweden		187.0
	ASII az checa Arb, Sweden		167.0
	Recovery of reimbursable expenses		
	AstraZeneca UK Limited, United Kingdom		29.8
	AstraZeneca AB, Sweden		33.7
	P.T. AstraZeneca Indonesia		14.6
	AstraZeneca Singapore Pte Ltd, Singapore		4.6
	AstraZeneca Pharmaceuticals LP, USA		6.6
	Cart the day of the said		
	Contribution to Trusts		
	AstraZeneca Pharma India Limited Management Staff Superannuation Fund Trust		6.3
	Start Superannuation Fund Trust		
(iii) (a) Transactions with Key Management Personnel		
	Salary and perquisites		
	Short-term employee benefits		37.6
	Long-term employee benefits		7.4
	Post employment benefits		15.1
	Employee share compensation expenses		2.3
	_		62.3
(iii) (b) Transactions with Independent Directors		
	Sitting fees paid to independent directors		1.7
(iv)	Details of balances receivable from and payable to	related parties as at 30 September, 2019 are as follows:	
	Other current financial assets		35.5
	AstraZeneca UK Limited, United Kingdom		28.0
	AstraZeneca Pharmaceuticals LP, USA		2.8
	AstraZeneca Singapore Pte Ltd, Singapore		2.1
	P.T. AstraZeneca Indonesia		2.7
	Trade receivables		121.1
	AstraZeneca AB, Sweden		121.1



690.9

614.4

74.5

2.0